No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Thursday, October 30, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

What Does Wall Street Think About Beam Therapeutics (BEAM)?

by TheAdviserMagazine
3 weeks ago
in Business
Reading Time: 2 mins read
A A
What Does Wall Street Think About Beam Therapeutics (BEAM)?
Share on FacebookShare on TwitterShare on LInkedIn


Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) on September 15, retaining the price target of $80.

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?

The analyst supported the optimistic rating with the company’s strong momentum in its in vivo and ex vivo base editing programs.

Similarly, in a report released on September 10, Kostas Biliouris from BMO Capital also maintained a Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) and set a price target of $40.00.

Biliouris supported the optimistic rating with the company’s technological advancements and strong position in the AATD market, adding that management’s confidence in the competitive positioning of BEAM-302 is a crucial reason for the bullish stance.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that develops precision genetic medicines through base editing, a technology that allows efficient and predictable single-base changes at targeted genomic sequences. The company’s lead programs focus on sickle cell disease and alpha-1 antitrypsin deficiency.

Beam Therapeutics Inc. (NASDAQ:BEAM) is advancing programs in other genetic diseases as well, along with oncology and immunology.

While we acknowledge the potential of BEAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.



Source link

Tags: BeamStreetTherapeuticsWall
ShareTweetShare
Previous Post

Monsoon and crop risks remain key to price volatility ahead: Pushan Sharma

Next Post

Best Health Insurance Plans in India for 2025

Related Posts

edit post
AI capex boosts from tech giants should benefit Credo, Micron, others: BNP Baripas

AI capex boosts from tech giants should benefit Credo, Micron, others: BNP Baripas

by TheAdviserMagazine
October 30, 2025
0

Oct. 30, 2025 12:03 PM ETMicrosoft Corporation (MSFT) Stock, GOOG Stock, GOOGL Stock, META StockCIEN, AMD, STX, WDC, NVDA, CLS,...

edit post
The uncomfortable secret of successful people: Forget work-life balance, you have to be ‘obsessed’, ex-Wall Streeter and business coach says

The uncomfortable secret of successful people: Forget work-life balance, you have to be ‘obsessed’, ex-Wall Streeter and business coach says

by TheAdviserMagazine
October 30, 2025
0

While casual side hustles can sometimes pay off, the most successful people prioritize their passion to turn it into profit. ...

edit post
Motilal Oswal Q2 Results: PAT plunges 68% YoY to Rs 362 crore, but posts record operating profit

Motilal Oswal Q2 Results: PAT plunges 68% YoY to Rs 362 crore, but posts record operating profit

by TheAdviserMagazine
October 30, 2025
0

Motilal Oswal Financial Services Ltd (MOFSL) reported 68% year-on-year (YoY) decline in its consolidated net profit at Rs 362 crore....

edit post
India to approve deals worth .7b for Israeli defense missiles

India to approve deals worth $3.7b for Israeli defense missiles

by TheAdviserMagazine
October 30, 2025
0

India's Defense Procurement Procedure Administration, headed by Minister of Defense Rajnath Singh, will meet on November 23 to approve...

edit post
TAQA to sell 250MW lignite power plant to India’s MEIL Energy

TAQA to sell 250MW lignite power plant to India’s MEIL Energy

by TheAdviserMagazine
October 30, 2025
0

Abu Dhabi National Energy Company (TAQA) has agreed to sell its entire stake in TAQA Neyveli Power Company to India-based...

edit post
Trinity Industries GAAP EPS of alt=

Trinity Industries GAAP EPS of $0.38, revenue of $454M (NYSE:TRN)

by TheAdviserMagazine
October 30, 2025
0

Trinity Industries press release (TRN): Q3 GAAP EPS of $0.38. Revenue of $454M (-43.2% Y/Y). 2025 Guidance Industry deliveries of...

Next Post
edit post
Best Health Insurance Plans in India for 2025

Best Health Insurance Plans in India for 2025

edit post
Why late-career savers need to be careful with RRSPs

Why late-career savers need to be careful with RRSPs

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Another Violent Outburst – Democrats Inciting Civil Unrest

Another Violent Outburst – Democrats Inciting Civil Unrest

October 24, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
The Factor Mirage: How Quant Models Go Wrong

The Factor Mirage: How Quant Models Go Wrong

0
edit post
Trump cuts fentanyl tariffs on China to 10% as Beijing delays rare earth curbs

Trump cuts fentanyl tariffs on China to 10% as Beijing delays rare earth curbs

0
edit post
Flutterwave, Polygon Team Up on Africa Stablecoin Payments

Flutterwave, Polygon Team Up on Africa Stablecoin Payments

0
edit post
Russian Oil Tanker Turns Back Under U.S. Sanctions Threat

Russian Oil Tanker Turns Back Under U.S. Sanctions Threat

0
edit post
Young Canadians sue CPP Investments over climate risks

Young Canadians sue CPP Investments over climate risks

0
edit post
Johnson & Johnson: Defensiver Basiswert mit Innovationshebel korrigiert zum EMA-50!

Johnson & Johnson: Defensiver Basiswert mit Innovationshebel korrigiert zum EMA-50!

0
edit post
Trump cuts fentanyl tariffs on China to 10% as Beijing delays rare earth curbs

Trump cuts fentanyl tariffs on China to 10% as Beijing delays rare earth curbs

October 30, 2025
edit post
Flutterwave, Polygon Team Up on Africa Stablecoin Payments

Flutterwave, Polygon Team Up on Africa Stablecoin Payments

October 30, 2025
edit post
How advisors are using AI tools for prospecting and growth

How advisors are using AI tools for prospecting and growth

October 30, 2025
edit post
Chart of the Week: The Fed’s AI Singularity Wake-Up Call

Chart of the Week: The Fed’s AI Singularity Wake-Up Call

October 30, 2025
edit post
Johnson & Johnson: Defensiver Basiswert mit Innovationshebel korrigiert zum EMA-50!

Johnson & Johnson: Defensiver Basiswert mit Innovationshebel korrigiert zum EMA-50!

October 30, 2025
edit post
AI capex boosts from tech giants should benefit Credo, Micron, others: BNP Baripas

AI capex boosts from tech giants should benefit Credo, Micron, others: BNP Baripas

October 30, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Trump cuts fentanyl tariffs on China to 10% as Beijing delays rare earth curbs
  • Flutterwave, Polygon Team Up on Africa Stablecoin Payments
  • How advisors are using AI tools for prospecting and growth
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.